TRANSTHERA-B has been included in the Hang Seng Composite Index and is expected to become a Hong Kong Stock Connect eligible stock

On August 22, Hang Seng Index Company announced the quarterly review results of the Hang Seng Index series as of June 30, 2025, in which TRANSTHERA-B was included in the Hang Seng Composite Index. The changes will take effect after the market closes on September 5 (Friday) and will be effective from September 8 (Monday). The Shanghai and Shenzhen Stock Exchanges will accordingly adjust the scope of investable stocks under the Hong Kong Stock Connect. According to a research report by Huatai Securities, TRANSTHERA-B may be included in the Hong Kong Stock Connect as it meets a series of criteria including market capitalization, liquidity, and listing time. TRANSTHERA announced that its self-developed multi-target kinase inhibitor TT-00420 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. The company stated that TT-00420 is currently in global Phase III registration trials as a multi-target kinase inhibitor, targeting FGFR/VEGFR, JAK, and Aurora kinases to exert anti-tumor effects. Ongoing clinical trials in the United States and China show its potential efficacy in the treatment of various solid tumors